You are here
FDA Accepts Gadofosveset NDA Filing, Contrast Agent for Magnetic Resonance Angiography
"The NDA submission for MS-325 was based on the results of a large Phase III clinical trial program that included four separate studies. We have been working actively with the FDA, and are pleased to move to the next stage of the review process," said Michael D. Webb, President and CEO of EPIX. " We believe that, if approved, MS-325-enhanced MRA will provide a safer way to perform diagnostic angiography. Given the risks that are associated with catheter X-ray angiography, many patients are contraindicated for either the X-ray contrast agent, or the procedure itself. MS-325 has the potential to help address this important medical need."
As previously announced in connection with full year 2003 financial results, a conference call is scheduled for 4:30 pm on February 17. Dial-in number for the EPIX conference call is 888-464-7607. A recording of this call will be available from 7:00 pm on February 17 through Friday, February 20, at 800-642-1687, reservation code 5468196. The call is being webcast by CCBN. The press release and the conference call webcast can also be found on the EPIX website at www.epixmed.com. An archived version will be available on the EPIX website two hours after the live webcast.
MS-325 binds reversibly to human serum albumin, brightening the blood for an extended period and allowing for magnetic resonance angiographic imaging of multiple vascular beds. This feature may allow physicians to collect more meaningful clinical data using widely available MRI equipment to diagnose and characterize vascular disease. MS-325-enhanced MRA is less invasive than current catheter-based X-ray angiography, and has the potential to provide health care professionals with an alternative to diagnose and manage patients with vascular disease. An NDA was submitted to the FDA in December, 2003.
Source: EPIX Medical, Inc.